Infections, caution in patients residing or travelling to endemic regions, do not give to patients w/ clinically important, active infection. TB, evaluate patients for TB risk factors & test patients for latent TB infections prior therapy, treat latent TB prior to therapy. Malignancies. Ped malignancy. Lymphoma. Leukemia. Malignancies other than lymphoma. Colon dysplasia/carcinoma. Skin cancers, to perform periodic skin exam. HBV reactivation, test patients for HBV infection before treatment. CHF, use with caution in patients w/ heart failure, monitor closely during therapy, discontinue if develop new or worsening symptoms of heart failure. Demyelinating disorders, discontinue if central or peripheral nervous system demyelinating disorders develop. Autoimmune processes, discontinue if patients develop symptom suggestive of lupus-like syndrome. Concomitant administration w/ anakinra, abatacept, other biological therapeutics. Switching between biological therapeutics. Hematologic reactions, exercise caution in patients who have current or past history of significant cytopenias. Live vaccines/therapeutic infectious agents, do not administer therapeutic infectious agents. Allergic reactions, latex sensitivity, hypersensitivity reactions, discontinue if anaphylactic or other serious allergic reaction occurs. Renal & hepatic impairment. Pregnancy & lactation. Childn <18 yr. Elderly.